Lexaria Bioscience Corp. Announces Further Phase 1b Study Results and Shares a Planned Share‑Sale

Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW) disclosed that it has completed additional secondary and exploratory endpoint analyses from its Phase 1b, 12‑week chronic study GLP‑1‑H24‑4, conducted in Australia. The study evaluated four DehydraTECH (DHT) formulations against a Rybelsus control arm. Chief Executive Officer Richard Christopher stated that the new data “adds to a growing dataset which showcases the many potential benefits of our platform technology – DehydraTECH.”

Key Points from the GLP‑1‑H24‑4 Update

  • Study Design: 12‑week chronic Phase 1b trial evaluating DHT formulations versus a commercial GLP‑1 control.
  • Results Summary: The company reports additional secondary and exploratory endpoint data, although specific numerical outcomes are not provided in the announcement.
  • Strategic Implication: The data is intended to further demonstrate the efficacy and safety profile of DehydraTECH‑semaglutide, potentially reducing GLP‑1 side effects and extending the company’s financial runway into 2026.

Planned Share Sale by Existing Stockholders

On December 29 2025, Lexaria Bioscience filed an application with the Securities and Exchange Commission for a secondary offering that would allow certain shareholders to sell 2.75 million shares of common stock. The filing notes that:

  • The company will not receive any proceeds from the sale.
  • The offering is a share‑sale by existing shareholders rather than a primary issuance.
  • The sale is intended to provide liquidity to the selling shareholders without affecting the company’s capital structure.

Market Context

  • The share sale follows the company’s announcement of additional Phase 1b data, which may influence investor perception of the company’s short‑term prospects.
  • The filing is consistent with prior disclosures that the company has explored multiple avenues to extend its cash runway, including potential capital‑raising activities.

Company Background

Lexaria Bioscience Corp. is a Canadian health‑care company listed on the Nasdaq. Its focus is on improving the pharmacokinetics of active pharmaceutical ingredients (APIs) through its DehydraTECH platform, which is applicable to a range of ingestible formats, including foods, beverages, oral suspensions, tablets, and capsules. The company operates a licensed in‑house research laboratory and maintains a substantial intellectual property portfolio. As of 28 December 2025, the company’s share price was $0.56, with a market capitalization of approximately $13.2 million. The 52‑week high was $2.43 and the 52‑week low was $0.46.